Stroke/Vascular Neurology News

High levels of patient engagement with nurse navigators after hospitalization for hemorrhagic stroke led to less disability and lower readmission rates after 90 days, according to research presented at International Stroke Conference.

The proportion of missed stroke diagnoses was more than four times higher in postpartum women with acute stroke compared with rates reported in nonmaternal populations, according to research presented at International Stroke Conference.

Cerebral amyloid angiopathy was associated with a higher risk for isolated nontraumatic subdural hemorrhage in two large, independent cohorts, according to research presented at International Stroke Conference.

Researchers observed no difference in 3-month functional outcomes or mortality among patients with acute ischemic stroke who underwent early BP-lowering therapy compared with a delayed strategy, a speaker reported.

Tenecteplase was noninferior to alteplase for acute ischemic stroke when given within 4.5 hours of symptom onset in patients not eligible for endovascular thrombectomy, according to research presented at International Stroke Conference.

Administration of Toll-receptor 4 antagonist ApTOLL within 6 hours of acute ischemic stroke, along with endovascular treatment, was linked to reduced mortality and disability at 90 days compared with placebo.

Lower target systolic BP after successful endovascular therapy demonstrated a signal of harm and only a marginal probability of benefit toward infarct volume and disability, a speaker reported.

Patients with large vessel occlusion strokes who underwent mechanical thrombectomy had lower mortality rates and higher rates of routine discharge in 2019 compared with 2020, although mortality rates shifted with surges of COVID-19.

Butylphthalide improved 90-day clinical outcomes in those with acute ischemic stroke who also received IV recombinant tissue plasminogen activator and/or endovascular treatment, per research presented at International Stroke Conference.

A secondary analysis of the phase 2 PACIFIC-STROKE trial showed that asundexian is effective for the secondary prevention of stroke in patients with stroke of atherosclerotic origin, but not those with small subcortical infarcts.